RxDoctor Payments Data

Ranga Krishna, MD

Neurology · Brooklyn, NYNPI 1730151218

Payments from drug & device makers

$19,393in general payments, 2019–2025

Across 1,017 payments — averaging $19.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • Novartis$2K
  • Scilex Pharmaceuticals Inc.$1K
  • Amgen$1K
  • Neurelis, Inc.$1K
  • Neurocrine Biosciences, Inc.$742
  • plus $11K from 54 others

What the payments were for

  • Speaking & faculty fees$890%
  • Food & beverage$19,304100%
  • Gifts$00%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)136$2,878
Novartis88$1,615
Scilex Pharmaceuticals Inc.67$1,100
Amgen(2 entities)34$1,030
Neurelis, Inc.37$1,013
Neurocrine Biosciences, Inc.33$742
Biogen31$655
Eisai Inc.28$640
Lilly USA, LLC34$587
Supernus Pharmaceuticals, Inc.26$552
Acadia Pharmaceuticals Inc29$533
UCB, Inc.44$500
Sunovion Pharmaceuticals Inc.25$489
AstraZeneca(2 entities)28$485
Mallinckrodt Hospital Products Inc.22$469
MDD US Operations, LLC13$461
ANI Pharmaceuticals, Inc.21$350
Sanofi19$331
Argenx US, Inc.16$307
Lundbeck LLC19$303
Vanda Pharmaceuticals Inc.16$280
SK Life Science, Inc.10$231
Acorda Therapeutics, Inc13$201
Adamas Pharmaceuticals, Inc.12$187
Bristol Myers Squibb11$185
Assertio Therapeutics, Inc.10$185
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC14$182
Collegium Pharmaceutical, Inc.12$167
Pfizer10$163
Daiichi Sankyo Inc.15$157
Johnson & Johnson6$136
Biodelivery Sciences International, Inc.8$131
Alnylam Pharmaceuticals Inc.6$116
Mallinckrodt Enterprises LLC7$111
Forte Bio-pharma LLC3$105
E.r. Squibb & Sons, L.L.C.6$100
Biohaven Pharmaceuticals, Inc.6$97
Akcea Therapeutics, Inc.7$93
Merck7$91
Almatica Pharma LLC6$88
Kyowa Kirin, Inc.5$81
Redhill Biopharma Inc.4$71
Greenwich Biosciences, Inc.5$70
Philips North America LLC4$65
Grifols USA, LLC4$64
Teva Pharmaceuticals USA, Inc.3$63
Axsome Therapeutics, Inc.4$63
Biohaven Pharmaceutical Holding Company Ltd.3$62
Bausch Health US, LLC3$57
Vertical Pharmaceuticals, LLC3$53
Immedica Pharma US, Inc.3$53
Azurity Pharmaceuticals, Inc.2$45
Kowa Pharmaceuticals America, Inc.3$42
Amneal Pharmaceuticals LLC3$40
Hikma Pharmaceuticals USA3$39
Merz Pharmaceuticals, LLC2$38
Catalyst Pharmaceuticals, Inc.2$36
Promius Pharma LLC3$35
Upsher-smith Laboratories LLC2$32
Zyla Life Sciences, Inc.2$31

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$19,393 in reported general payments places this provider in the 75th percentile of 1,623 neurology providers in New York.

See all neurology providers in New York

Medicare billing

Part B allowed, 2024
$685,425
Medicare patients
698
Services billed
5,647

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Kesimpta PenOfatumumab24$202,358
UbrelvyUbrogepant126$190,807
AubagioTeriflunomide13$123,941
Nurtec OdtRimegepant Sulfate40$73,621
Diclofenac Sodium207$73,401
QuliptaAtogepant46$54,958
NucyntaTapentadol Hcl57$43,527
PercocetOxycodone Hcl/Acetaminophen13$33,030
ZtlidoLidocaine77$27,706
Emgality PenGalcanezumab-Gnlm26$22,793
Nucynta ErTapentadol Hcl15$19,470
ValtocoDiazepam14$16,591
Diclofenac Potassium17$14,862
OzempicSemaglutide14$14,839
Trokendi XrTopiramate29$14,239

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieUbrelvy, Qulipta, Linzess$2,878$254,063188 claims
SanofiAubagio$331$123,94113 claims
PfizerNurtec Odt$163$73,62140 claims
Collegium Pharmaceutical, Inc.Nucynta, Nucynta Er$167$62,99772 claims
Scilex Pharmaceuticals Inc.Ztlido$1,100$27,70677 claims
Neurelis, Inc.Valtoco$1,013$16,59114 claims
Supernus Pharmaceuticals, Inc.Trokendi Xr$552$14,23929 claims
UCB, Inc.Neupro$500$11,42414 claims
MerckBelsomra$91$8,35019 claims
Redhill Biopharma Inc.Movantik$71$6,23314 claims
Amneal Pharmaceuticals LLCRytary$40$5,71119 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,623 neurology providers in New York.

Other neurology in Brooklyn

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →